Escalating anti-tumour necrosis factor exposure with reductions in surgical resection rates in paediatric inflammatory bowel disease: an 18-year real-world population-based cohort study - Quiz - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Increasing Exposure to Anti-Tumour Necrosis Factor and Its Impact on Surgical Resection Rates in Pediatric Inflammatory Bowel Disease: An 18-Year Population-Based Cohort Analysis

  • By

  • Zachary Green

  • Myrna Nicholas

  • Stephanie Vuijk

  • Mike Stanton

  • Christopher Bakewell

  • Tracy Coelho

  • Akshay Batra

  • Nadeem A Afzal

  • Sarah Ennis

  • Robert Mark Beattie

  • James Ashton

  • June 24, 2026

Share

Original Source(s)

Escalating anti-tumour necrosis factor exposure with reductions in surgical resection rates in paediatric inflammatory bowel disease: an 18-year real-world population-based cohort study

  • by Zachary Green, Myrna Nicholas, Stephanie Vuijk, Mike Stanton, Christopher Bakewell, Tracy Coelho, Akshay Batra, Nadeem A Afzal, Sarah Ennis, Robert Mark Beattie, James Ashton

  • June 24, 2026

Related Content

Engineered Escherichia coli Nissle 1917 secreting anti-TNF-α nanobody as a single-strain live biotherapeutic for inflammatory bowel disease

Shared inflammatory architecture and therapeutic tensions between psoriasis and Crohn’s disease

Efficacy of Ustekinumab for the treatment of perianal fistulizing Crohn’s disease: a multicentre retrospective study